ODTX

Odyssey Therapeutics, Inc. ODTX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$0

Quarter to Jun 30

Net income

$-52.79M

Quarter to Jun 30

Free cash flow

$-34.69M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$652.88M total
FMR LLC
$96.90M--
SR ONE CAPITAL MANAGEMENT, LP
$71.00M--
TPG GP A, LLC
$69.04M--
Lightspeed Management Company, L.L.C.
$67.51M--
ORBIMED ADVISORS LLC
$56.15M--
Sanofi
$37.27M--
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$19.57M--
Sands Capital Ventures, LLC
$16.37M--
Hillhouse Capital Advisors, Ltd.
$15.56M--
General Catalyst Group Management, LLC
$15.16M--
Affinity Asset Advisors, LLC
$14.34M--
ADAGE CAPITAL PARTNERS GP, L.L.C.
$13.56M--
VANGUARD CAPITAL MANAGEMENT LLC
$13.48M--
Foresite Capital Management V, LLC
$13.34M--
Vivo Capital, LLC
$10.76M--
EcoR1 Capital, LLC
$10.39M--
Logos Global Management LP
$9.76M--
MARSHALL WACE, LLP
$9.22M--
PRICE T ROWE ASSOCIATES INC /MD/
$8.83M--
Catalio Capital Management, LP
$8.57M--
Redmile Group, LLC
$7.95M--
BALYASNY ASSET MANAGEMENT L.P.
$7.37M--
Woodline Partners LP
$6.47M--
FRANKLIN RESOURCES INC
$5.15M--
Boxer Capital Management, LLC
$5.15M--
See all 59 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ODTX

Earnings Per Share

13fpro.ai/company/ODTX

Loading ratio trend…

About Odyssey Therapeutics, Inc. (ODTX): stock profile, AI score and financials

Odyssey Therapeutics, Inc. (ODTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ODTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Odyssey Therapeutics, Inc. reports net income of $-52.8M, free cash flow of $-34.7M. Top institutional holders of ODTX by reported 13-F value include FMR, SR ONE CAPITAL MANAGEMENT, TPG GP A, based on the most recent SEC filings. ODTX trades on the Nasdaq exchange and files with the SEC under CIK 1882782. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ODTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Odyssey Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1882782 →